

01.01.2013

**CURRICULUM VITAE**

***Oscar F. Ballester, M.D.***

**LUGAR Y FECHA DE NACIMIENTO:** Buenos Aires, Argentina  
September 20, 1949

**ESTADO CIVIL:** Casado  
Tres hijos: Barbara, Paola, y Sebastian

**DOMICILIO:** Armenia 2245, 5to A  
Ciudad Autonoma de Buenos Aires 1425

**EDUCACION Y POSTGRADO:** Medico, Universidad Nacional de Cordoba, Argentina  
Diciembre, 1971

**Internado:** Huron Road Hospital,  
Cleveland, Ohio  
Juliio 1972 - Junio 1973

**Residencia, Medicina Interna:** Detroit General Hospital  
Detroit, Michigan  
Julio 1973 - Julio 1975

**Jefe de Residentes:** Departamento de Medicina, Policlinico Ferroviario Central  
Buenos Aires, Argentina  
Mayo 1976 - Abril 1977

**Fellowship, Hematologia:** Wayne State University  
Detroit, Michigan  
July 1977 - June 1979

**Fellowship, investigacion:  
(Hematologia)** Wayne State University  
Detroit, Michigan  
July 1979 - June 1980

**Fellowship, Oncologia:** H. Lee Moffitt Cancer Center  
University of South Florida  
Tampa, Florida  
January 1988 - December 1988

**LICENCIATURA:** Michigan, 1978  
Florida, 1987  
Illinois, 1997  
New York, 2000  
Georgia, 2002  
Louisiana, 2005  
West Virginia, 2007

**CERTIFICADOS  
DE ESPECIALIZACION:** American Board of Internal Medicine, 1980  
ABIM, Hematology, 1988  
ABIM, Oncology, 1989

**OTROS CERTIFICADOS:** E.C.F.M.G., 1972  
F.L.E.X., 1978  
V.Q.E. 1980

**PREMIOS:**

First Prize Award Essay Competition, 1973  
Huron Road Hospital,  
Cleveland, Ohio

O. Ballester and H. Rubinstein:  
Isolated left anterior hemiblock in acute myocardial infarction

**POSICIONES ACADEMICAS:**

Instructor: Department of Medicine  
Wayne State University  
Detroit, Michigan  
July 1980 - December 1980

Profesor Asistente: Department of Medicine  
Division of Hematology  
Wayne State University  
Detroit, Michigan  
January 1981 - July 1984

Instructor: Department of Medicine  
Medical Oncology  
University of South Florida  
Tampa, Florida  
January 1989 - May 1989

Profesor Asistente: Department of Medicine  
Division of Hematology  
University of South Florida  
June 1989 - June 1992

Profesor Asistente: Department of Medicine  
Division of Bone Marrow Transplantation  
University of South Florida  
July 1992 - July 1997

Profesor Asociado Department of Medicine  
Division of Bone Marrow Transplantation  
University of South Florida  
August 1997-September 1997

Profesor Asociado: Divisions Hematology/Medical Oncology  
Cancer Center of Albany Med  
Albany Medical College  
Albany, New York  
November 2000 – June 2002

Director de Programa: Blood and Bone Marrow Transplantation Program  
Cancer Center of Albany Med  
Albany Medical College  
Albany, New York  
November 2000 – June 2002

Director de Programa: Hematology Fellowship Program  
Department of Medicine  
Albany Medical College  
Albany, New York  
November 2000 – June 2002

Director, Investigacion Hematologia: Cancer Center of Albany Med  
Section, Hematology  
Albany Medical College  
Albany, New York  
November 2000 – June 2002

Profesor: Department of Medicine  
Section, Hematology/Oncology  
Medical College of Georgia  
Augusta, Georgia  
July 2002 – June 2005

Director: Bone Marrow Transplant/  
Hematological Malignancies Program  
Medical College of Georgia  
Augusta, Georgia  
July 2002 – June 2005

Director Investigacion Hematologia: Feist Weiller Cancer Center  
Louisiana State University  
Shreveport, LA  
October 2005 – May 2007

Profesor: Edwards Comprehensive Cancer Center  
Marshall University  
Huntington, WV  
June 2007 – November 2011

#### **OTHER POSICIONES:**

Medico Oncologo: Northwest Internal Medicine Associates  
Providence Hospital  
Southfield, Michigan  
October 1985 - December 1987

Director: Bone Marrow Transplant Program  
Midwestern Regional Medical Center  
Zion, Illinois  
September 1997 – November 2000

#### **ACTIVIDADES EDUCATIVAS:**

1. Clinical Laboratory Hematology Course 1990 to 1997  
College of Medicine, USF
2. Pathobiology of neoplasia (NGR 6142) 1990 to 1997  
College of Nursing, USF

#### **OTRAS ACTIVIDADES:**

V.A. HOSPITAL

1. Member, Commodity Standards Committee, James A. Haley V.A. Hospital - 1992
2. Member, Blood Utilization Committee, James A. Haley V.A. Hospital - 1992

#### MOFFITT CANCER CENTER

1. Member, Blood Utilization Committee, H. Lee Moffitt Cancer Center - 1997

#### **AFILIACION A SOCIEDADES MEDICAS:**

1. Mlembro, American Society of Hematology; 1991 - Present
2. Miembro, International Society for Experimental Hematology; 1993 - Present
3. Miembro, New York Academy of Sciences; 1996 - Present

#### **EXPOSITOR INVITADO EN CONFERENCIAS:**

1. Sickle cell anemia: Infection and Immunity  
Department of Medicine Grand Rounds  
University of South Florida  
October 1989  
Tampa, Florida
2. Sickle cell anemia  
In-service Program  
Lee Moffitt Cancer Center  
April 1990  
Tampa, Florida
3. Clinical and laboratory approach to the anemic patient  
MKSAP review course  
American College of Physicians  
August 1990  
Orlando, Florida
4. Lymphoproliferative Disorders  
MKSAP review course  
American College of Physicians  
August 1990  
Orlando, Florida
5. Diagnosis and Treatment of Anemia: A Review of Recent Advances  
Hematology Update: 1990  
University of South Florida  
September 1990  
Clearwater Beach, Florida
6. Multiple Myeloma  
Hematology Update: 1990  
University of South Florida  
September 1990  
Clearwater Beach, Florida
7. Multiple Myeloma  
Department of Medicine Grand Rounds  
University of South Florida  
October 1990  
Tampa, Florida

8. Hemopoietic Growth Factors: Clinical Applications  
Fifth Educational and Scientific Program  
Association of American Physicians from South Asia  
March 1991  
Tampa, Florida
9. Role of Growth Factors in the Management of Non-malignant Hemopoietic Failure  
Hemopoietic Growth Factors Symposium  
March 1991  
St. Petersburg, Florida
10. Clinical and Laboratory Approach to the Patient with Anemia  
Internal Medicine Review Course  
American College of Physicians  
August 1991  
Lake Buena Vista, Florida
11. Hodgkin's Disease and Multiple Myeloma  
Internal Medicine Review Course  
American College of Physicians  
August 1991  
Lake Buena Vista, Florida
12. Acute Leukemia and Malignant Lymphoma in the Geriatric Population Symposium on Aging Trends  
in Geriatric Oncology  
117th Annual Meeting Florida Medical Association  
September 1991  
Orlando, Florida
13. Acute Leukemia in the Elderly  
Leukemia: The Forecast for 1991  
Leukemia Society of America  
Morton Plant Hospital  
November, 1991  
Clearwater, Florida
14. Biology of Multiple Myeloma  
First International Conference on Geriatric Oncology  
October, 1992  
Buenos Aires, Argentina
15. Role of Growth Factors in the Management of Malignant  
and Non-Malignant Hematopoietic Failure in the Elderly  
American Geriatric Society  
November, 1992  
Washington, DC
16. Allogeneic Transplants for Myeloma  
"Bone Marrow Transplantation in the 90's"  
Lee Moffitt Cancer Center  
February, 1993  
Tampa, Florida
17. Bone Marrow Transplantation  
American-Argentinian Medical Association  
Scientific Symposium  
April, 1993  
St. Louis, Missouri
18. Multiple Myeloma - New Treatment for an Old Disease

"Bone Marrow Transplantation Comes to Halifax"  
Halifax Medical Center  
July, 1993  
Daytona Beach, Florida

19. Interleukin-6  
Autologous Bone Marrow Transplants For Lung Cancer  
XI Argentinian Congress on Clinical Oncology and  
IV Latin American Oncology Congress  
September, 1993  
Buenos Aires, Argentina
20. Multiple Myeloma  
Diagnosis and Management of Lymphoid Malignancy in the Elderly Patient  
American Geriatric Society  
November , 1993  
New Orleans, Louisiana
21. Progress In Multiple Myeloma, Biology and Treatment  
Leukemia, Lymphoma and Multiple Myeloma: Progress to the End of the Century  
Leukemia Society of America  
November, 1993  
Tampa, Florida
22. Autologous Bone Marrow Transplants for Breast Cancer  
Clinical Use of colony-Stimulating Growth Factors  
August 17-18, 1994  
Universidad del Norte  
Barranquilla, Colombia
23. Multiple Myeloma  
IV International Meeting in Oncology  
Oncology Society of Cordoba  
August 17-20, 1994  
Cordoba, Argentina
24. IL-6, Aging and Multiple Myeloma  
Second International Conference on Geriatric Oncology  
September 19-21, 1994  
Genova, Italy
25. New Strategies in Multiple Myeloma  
Future directions in the treatment of Hematologic Malignancies  
September 22-23, 1995  
Hilton Head Island, North Carolina
26. Multiple Myeloma: Progress in biology and treatment  
Sylvester Cancer Center  
University of Miami  
September 27, 1995  
Miami, Florida
27. Multiple Myeloma: Progress in biology and treatment  
Department of Medicine Grand Rounds  
University of South Florida  
January 4, 1996  
Tampa, Florida
28. Multiple Myeloma: Treatment of bone disease  
International Myeloma Foundation Seminar

June 15, 1996.  
Miami Beach, Florida

29. Bone Marrow Transplantation for Multiple Myeloma  
International Myeloma Foundation Seminar  
May, 1997.  
Houston, Texas
30. Novel Induction Regimens: DC-IE  
IV International Workshop on Multiple Myeloma  
June 1997  
Boston, Massachusetts
31. Bone Marrow Transplantation for Multiple Myeloma  
International Myeloma Foundation Seminar  
May 1998  
Miami, Florida.
32. Idarubicin-based combination chemotherapy for multiple myeloma.  
2nd International Symposium on Malignant Lymphomas  
September 1998  
Munich, Germany.
33. Multiple Myeloma in the Elderly  
4th International Meeting on Geriatric Oncology  
October 1998.  
Rome, Italy.
34. Clinical Trials in Multiple Myeloma  
International Myeloma Foundation  
September 2003  
Atlanta, Georgia
35. Hematological Malignancies in the elderly patient.  
Georgia Academy of Family Physicians  
October 2003  
Atlanta, Georgia
36. International Myeloma Foundation Patient Seminar  
October 2003  
Atlanta, GA

#### **CAPITULOS EN LIBROS:**

1. Ballester OF, Balducci L, Saba HI. Approach to the management of Multiple Myeloma in the elderly patient. In Geriatric Oncology. Balducci L, Lyman G and Erschler W, editors. J.B. Lippincott, publisher. 1992.
2. Ballester OF, Balducci L, Saba HI. Acute Myelogenous Leukemia in the elderly. In Geriatric Oncology. Balducci L, Lyman G and Erschler W, editors. J. B. Lippincott, publisher. 1992.
3. Fields K, Eifenbein G, Perkins J, Ballester O, Hiemenz J, Zorsky P. Event-free survival in breast cancer patients treated with high-dose ifosfamide, carboplatin and etoposide and autologous stem cell rescue: Analysis of risk factors. (Einhorn J, Nord C, and Norrby S, Eds) Recent Advances in Chemotherapy, Proceedings of the 18th International Congress of Chemotherapy. Washington, DC, pp. 974-975, 1994.
4. Janssen WE, Smilee R, Carter R, Rahn D, Cairo M, Hiemenz JW, Zorsky PE, Fields KK, Ballester

- O, Perkins J, Kronish L, Eifenbein GJ. Mobilization of peripheral blood stem cells (PBSC): Comparing cyclophosphamide and growth factor based regimens. In: *Advances in Bone Marrow Purging and Processing* (In the series Prog Clin Biol Res #389). (Worthington-White D, Gee A, Gross S, Eds) Wiley-Liss, New York, pp. 429-439, 1994.
5. Janssen WE, Eifenbein GJ, Fields KK, Hiemenz JW, Zorsky PE, Ballester OF, Goldstein SC, Smilee R, Kronish L, Beach B, and LeParc G. Comparison of cell collections and rates of post-transplant granulocyte recovery when G-CSF and CM-CSF are used as mobilizers of peripheral blood stem cells for autotransplantation. In: *Autologous Bone Marrow Transplantation, Proceedings of the 7th International Symposium*. (Dicke KA, Keating A, Eds) Arlington, pp. 527-539, 1995.
  6. Garland LL, Ballester OF, Vasey FB, Benson K, Moscinski LC, Farmelo MJ, Rodriguez MJ, Rapaport DP. Multiple Myeloma in women with silicone breast implants. Serum immunoglobulin and interleukin-6 studies in women at risk. In *Immunology and Silicones, Current Topics in Microbiology and Immunology*. (M Potter and N Rose, Eds). Springer, Germany, pp.361-366, 1996.
  7. Rabkin CS, Silverman S, Tricot G, Garland LL, Ballester O, Potter M. The National Cancer Institute Silicone Implant/Multiple Myeloma Registry. In *Immunology of Silicones, Current Topics in Microbiology and Immunology*. (M Potter and N Rose, Eds). Springer, Germany, pp 385-388, 1996.
  8. Ballester O, Corrado C, Vesole D. Multiple Myeloma in the older patient. In *Geriatric Oncology*. (L Balducci, Lyman G, Ershler WB, Ed) Harwood Academic Publishers, The Netherlands, pp 595-609, 1998.
  9. Ballester G, Ballester O, Corrado C and Vesole D. Advances in the treatment of multiple myeloma in the elderly patient. (Balducci L, Lyman G, Ershler WB, Extermann M, Eds). Taylor & Francis Publishers. UK 2004.
  10. Bruno S, Mazzella F and Ballester O. Acute lymphoblastic leukemia in elderly patients: diagnosis and therapy. In *Blood disorders in the elderly* (L Balducci, W Ershler, G De Gaetano, editors) Cambridge Publishers, UK 2007.
  11. Ballester O, Munker R, Lazarus H, Atkinson K. Therapeutic decision making in hematopoietic stem cell transplantation for multiple myeloma. In *The BMT Data Book* (R Munker, H Lazarus, K Atkinson, editors) Cambridge University Press, UK 2009.

#### **PUBLICACIONES:**

1. Freytes MA, Posseto H and Ballester OF: Gastric secretion, erythrocytes and hemoglobin. *Rev Esp Enf Apar Dig* 31:49-52, 1970.
2. Freytes MA, Posseto H, Rebora E and Ballester OF: Lactose Tolerance test and medical vagotomy. *Rev Esp Eng Apar Dig* 34:395-398, 1971.
3. Ballester OF and Warth J: Sickle cell anemia: recurrent splenic pain relieved by splenectomy. *Ann Intern Med* 90:349-350, 1979.
4. Ballester OF, Shurafa M, Toben H, Kumar K and Burek C: Impaired antibody responses to a pneumococcal polysaccharide vaccine in patients with Non-Hodgkin's Lymphoma in remission. *J Clin Immunol* 1:90-93, 1981.
5. Ballester OF and Prasad A: Anergy, zinc deficiency and decreased nucleoside phosphorylase activity in patients with sickle cell anemia. *Ann Intern Med* 98:180-182, 1983.
6. Ballester OF, Abdallah JM and Prasad A: Impaired IgM antibody responses to an influenza virus vaccine in adults with sickle cell anemia. *Am J Hematol* 20:409-412, 1985.
7. Ballester OF, Abdallah JM and Prasad A: Lymphocyte sub-population abnormalities in sickle cell



- anemia: distinctive pattern from that of AIDS. *Am J Hematol* 21:23-27, 1986.
8. Ballester OF, Saba HI, Moscinski LC, Nelson R, Foulis P: Pure Red Cell Aplasia (PRCA); Treatment with intravenous immunoglobulin (IVIg) concentrate. *Semin Hematol* 29:106-108, 1992.
  9. Ballester OF, Moscinski L, Morris D, Balducci L. Acute myelogenous leukemia in the elderly. *J Am Geriat Soc.* 40:277-284, 1992.
  10. Garland L, Cadigan B, Ballester OF, Saba HI. Acquired factor VIII deficiency and polyradiculoneuropathy. *N Eng J Med* 324:1139, 1992. (Letter)
  11. Saba HI, Ballester OF. Hemopoietic Growth Factors in Myelodysplasia. *Hematol Reviews* 5:207-221, 1992.
  12. Ballester OF, Saba HI. Role of Growth Factors in the Management of Non-Malignant Hemopoietic Failure. *Hematol Reviews* 5:223-227, 1992.
  13. Ballester OF, Wang T, Saba HI, Morelli G, Tantranond P and Balducci L. Classic Hemophilia in Elderly Patients. *J Am Geriat Soc* 40:824-826, 1992.
  14. Edwards TB, Nelson RP, Ballester OF, Saba HI, Lockey RF. Polycythemia as a Complication of HIV infection. *South Med J* 86:686-688, 1993.
  15. Balducci L, Benson K, Lyman G, Sanderson R, Fields K, Ballester O, and Eifenbein G. Cost-effectiveness of leukocyte depleting filters in adult acute myelogenous leukemia. *Transfusion* 33:665-670, 1993.
  16. Ballester OF. Allogeneic bone marrow transplantation for multiple myeloma. *Semin Oncol.* 20 (Suppl 6):67-71, 1993.
  17. Fields KK, Eifenbein GJ, Perkins JB, Hiemenz JW, Janssen WE, Zorsky PE, Ballester OF, Kronish LE, Foody MC. Two novel high dose treatment regimens for metastatic breast cancer: ifosfamide, carboplatin plus etoposide (ICE) and mitoxantrone plus thiotepa (MITT): outcomes and toxicities. *Semin Oncol.* 20 (Suppl 6):59-66, 1993.
  18. Benson K, Fields K, Hiemenz J, Zorsky P, Ballester O, Perkins J, Eifenbein G. The platelet refractory bone marrow transplant patient: Prophylaxis and treatment of bleeding. *Semin Oncology* 20 (suppl 6):102-109, 1993.
  19. Ballester OF, Moscinski L, Spiers A, Balducci L. Non-Hodgkin's lymphoma in the older person: A review. *J Am Geriat Soc,* 41:1245-1254, 1993.
  20. Virgilio J, Moscinski L, Ballester O, Corrado C, Guida C, Balducci, Saba H. Acute lymphocytic leukemia (ALL) in elderly patients. *Hematol. Oncol.* 11:121-126, 1993.
  21. Ballester OF, Moscinski LC, Lyman GH, Chaney JV, Saba HI, Spiers ASD, Klein C. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. *Blood* 83:1903-1908, 1994.
  22. Janssen, WE, Hiemenz W, Fields KK, Zorsky PE, Ballester OF, Goldstein SC, Eifenbein GJ. Blood and bone marrow hematopoietic stem cells for transplantation. *Cancer Control* 1: 225-230, 1994.
  23. Ballester OF, Eifenbein GJ. A rational appraisal of bone marrow transplantation and immunosuppressive therapy for severe plastic anemia. *Cancer Control* 1: 208-212, 1994.
  24. Fields KK, Agalotis DP, Janssen, WE, Perkins JB, Ballester OF, Hiemenz JW, Zorsky PE, Eifenbein GJ. High-dose chemotherapy and the treatment of metastatic breast cancer: Selecting the regimen and the source of stem cells. *Cancer Control* 1: 213-218, 1994.
  25. Fields KK, Eifenbein GJ, Perkins JB, Janssen WE, Ballester OF, Hiemenz JW, Zorsky PE, Kronish

- LE, and Foody MC. High-dose ifosfamide/carboplatin/etoposide: Maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion. *Semin Oncol* 21 (suppl 12):86-92, 1994.
26. Moscinski LC, Ballester OF. Recent Progress in Multiple Myeloma. *Hematol Oncol* 12: 111-123, 1994.
  27. Fields K, Effenbein G, Lazarus H, Cooper B, Perkins J, Creger R, Ballester O, Hiemenz J, Janssen W, Zorsky P. Maximum tolerated doses of ifosfamide, carboplatin and etoposide given over six days followed by autologous stem cell rescue: Toxicity profile. *J Clin Onc* 13: 3223-332, 1995.
  28. Ramirez G, Bittle PA, Rabb HA, Ballester O, Bercu BB. Effect of hemoglobin and endogenous erythropoietin on hypothalamic-pituitary thyroidal and gonadal secretion: an analysis of anemic (high EPO) and polycythaemic (low EPO) patients. *Clin Endocrinol* 43:167-174, 1995.
  29. Spiers ASD, Saba HI, Ballester OF, Moscinski LC, Morgan MB, Williams EC. Purple people with lymphoid neoplasms: a new clinical and pathological syndrome. *Hematol Reviews* 9:197-204, 1995.
  30. Berman BS, Lyman GH, Ballester OF, Sanderson RA, Spiers ASD. Therapeutic use of granulocyte colony stimulating factor after induction chemotherapy in acute myelogenous leukemia: an analysis of clinical practice. *Hematol Reviews* 9:213-221, 1995.
  31. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simone J, Reitsma JD, Heffernan M, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal-related events in patients with advanced multiple myeloma. *N Engl J Med* 334: 488-493, 1996.
  32. Ballester OF, Agalotis DP, Hiemenz JW, Janssen JW, Fields KK, Zorsky PE, Goldstein SC, Perkins JB, Effenbein GJ. Phase I-II study of high dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery. *Bone Marrow Transplantation*, 18: 9-14, 1996.
  33. Ballester OF, Moscinski LC, Fields KK, Hiemenz JW, Zorsky PE, Goldstein SC, Saba HI, Spiers ASD, Kronish L, Sullivan P, Effenbein GJ. Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): A novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma. *Brit J Hematol* 96:746-748, 1997.
  34. Ballester OF, Tumala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, Perkins JB, Sullivan DM, Rosen R, Sackstein R, Zorsky P, Saez R, Effenbein GJ. High dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. *Bone Marrow Transplantation* 1997;20:653-656.
  35. Crucian BE, Moscinski LC, Androlewicz M, Ballester OF, Widen RH, Yu H. Assessment of intracellular TAP-1 and TAP-2 in conjunction with surface MHC class I in plasma cells from patients with multiple myeloma. *Br J Haematol* 1997, 98: 426-432.
  36. Maurtua MA, Moscinski LC, Messina J, Miller L, Ballester OF. Type III Hypersensitivity Reaction with the use of Interferon-alpha. *Am J Hematol* 1997, 55(1):53-4
  37. Agalotis DP, Ballester OF, Mattox T, Hiemenz JW, Fields KK, Zorsky PE, Goldstein SC, Perkins JB, Rosen RM, Effenbein GJ. Nephrotoxicity of High-Dose Ifosfamide/Carboplatin/Etoposide in Adults Undergoing Autologous Stem Cell Transplantation. *Am J Med Sci* 1997, 314(5):292-8
  38. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD. Long-Term Pamidronate Treatment of Advanced Multiple Myeloma Patients Reduces Skeletal Events. Myeloma Aredia Study Group. *J Clin Oncol* 1998, 16(2):593-602
  39. Turner JG, Tan J, Crucian BE, Sullivan DM, Ballester OF, Dalton WS, Yang NS, Burkholder JK, Yu H. Broadened Clinical Utility of Gene Gun-Mediated Granulocyte-Macrophage Colony-Stimulating

Factor cDNA-Based Tumor Cell Vaccines as Demonstrated with a Mouse Myeloma Model. *Hum. Gene Therapy* 1998, 9:1121-1130.

40. Fields KK, Effenbein GJ, Perkins JB, Ballester OF, Goldstein SC, Heimenz JW, Saez RA, Sullivan DM, Partyka JS, Kronish LA. Defining the Role of Novel High-Dose Chemotherapy Regimens for the Treatment of High-Risk Breast Cancer. *Semin Oncol* 1998, 25(2 Suppl 4):1-6; discussion 45-8
41. Vescio R, Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard, Schlossman R, Brown R, Tully H, Menyunes M, Jacobs C, Berenson R, DiPersio J, Anderson K, Berenson J. Multicenter Phase III Trial to Evaluate CD34+ Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma. *Blood* 1999, 93(6):1-13
42. Krieger MS, Schiller G, Berenson JR, Stewart K, Noga SJ, Ballester OF, Tarantolo S, Stiff P, Kuhn D, Scherzo E, Sing A, Jacobs C, White JM, DiPersio J. Collection of Peripheral Blood Progenitor (PBPC) Based on a Rising WBC and Platelet Count Significantly Increases the Number of CD34+ cells. *Bone Marrow Transplant* 1999, 24(1):25-8
43. Vescio RA, Wu CH, Zheng L, Sheen D, Ma H, Liu J, Stewart AK, Ballester O, Noga SJ, Rugo H, Freytes C, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Schiller GJ, White M, Jacobs C, DiPersio J, Anderson KC, Berenson JR. Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograph products from multiple myeloma patients. *Bone Marrow Transplant* 2000, 25(2):153-160
44. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, White M, DiPersio J, Anderson KC, Berenson J. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. *J Clin Oncol*. 2001 Sep 1;19(17):3771-9.
45. Bruno GV, Ballester OF. Bone Marrow Transplantation. *Current Clinical Practice: High-Dose Chemotherapy and Stem Cell Transplantation for Non-Hodgkin's Lymphoma: Review of Recent Advances*. *Hematol*. 2000;5(2):87-101.
46. Ballester OF, Fang T, Raptis A, Ballester G, Wilcox P, Hiemenz J, Tan B. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma. *Bone Marrow Transplantation* 2004 , 34: 419-423 .
47. Kuthiala SK, Lyman GH, Ballester O. Randomized clinical trials for Hematopoietic Stem Cell Transplantation: lessons to be learned from the European experience. *Bone Marrow Transplant* 2006; 37: 219-21.
48. Ballester G, Tirona MT, Ballester O. Hematopoietic stem cell transplantation in the elderly. *Oncology*, 2007; 21:1576-83.
49. Ballester O. The emperor's new clothes or the current practice of clinical trials for multiple myeloma in the USA. *Cancer Invest*. 2008; 26:445-7.
50. Witte TR, Salazar AJ, Ballester OF, Hardman WE. RBC and WBC fatty acid composition following consumption of an omega 3 supplement: lessons for future clinical trials. *Lipids Health Dis*. 2010 Mar 22;9:31.
51. Tirona MT, Sehgal R, Ballester O. Prevention of breast cancer (Part I): epidemiology, risk factors, and risk assessment tools. *Cancer Invest*. 2010; 28:743-50.
52. Tirona MT, Sehgal R, Ballester O. Prevention of breast cancer (Part II): risk reduction strategies. *Cancer Invest*. 2010; 28:1070-7.
53. Fahrman JF, Ballester OF, Ballester G, Witte TR, Salazar AJ, Kordusky B, Cowen KG, Ion G, Primerano DA, Boskovic G, Denvir J, Hardman WE. Inhibition of Nuclear Factor Kappa B activation

in Early-Stage Chronic Lymphocytic Leukemia by Omega-3 Fatty Acids. Cancer Investigation. In press, posted online on 29 Nov 2012.

#### **TRABAJOS PRESENTADOS EN REUNIONES CIENTIFICAS:**

1. Ballester OF, Shurafa M, Toben H, Kumar K, Lewkow L and Burek C: Antibody responses to a pneumococcal polysaccharide vaccine in patients with "B" cell malignancies. American College of Physicians, Michigan Chapter. October 1980.
2. Ballester OF and Prasad A: Anergy, zinc deficiency and decreased nucleoside phosphorylase activity in patients with sickle cell anemia. Annual Meeting of the Central Society for Clinical Research, Chicago, Illinois. November 1981.
3. Ballester OF, Prasad A: Anergy, zinc deficiency and decreased nucleoside phosphorylase activity in patients with sickle cell anemia. Annual Meeting of the Nat'l Sickle Cell Disease Program. Hilton Head Island, SC. December 1981.
4. Ballester OF, Abdallah JM and Prasad A: Lymphocyte sub-population abnormalities in sickle cell anemia: a distinctive pattern from that of AIDS. Annual Meeting of the Central Society for Clinical Research. Chicago, Illinois. November 1984.
5. Ballester OF, Saba HI, Moscinski LC, Nelson R, Foulis P: Pure Red Cell Aplasia (PRCA): Treatment with intravenous immunoglobulin (IVIg) concentrate. "IVIg: Current Role in Bone Marrow Transplant, Malignancy and Immune hematologic Disorders". Georgetown University Medical Center, Scottsdale, Arizona. October 1990.
6. Ballester OF, Morelli GA, Saba HI, Foulis P. An IgG, time-dependent, acquired factor V (FV) inhibitor. American Society of Hematology Annual Meeting, Boston, Massachusetts. December 1991.
7. Ballester OF, Saba HI, Morelli GA, Balducci L, Fabri PJ. Heparin-induced thrombocytopenia (HIT) and thrombosis in an elderly patient. American Geriatrics Society Annual Meeting, Chicago, Illinois. May 1991.
8. Ballester OF, Wang T, Saba H, Morelli G, Trantranond P. Hemophilia A in Elderly Patients. XII International Congress on Hemostasis and Thrombosis, Buenos Aires, Argentina. November 1991.
9. Moscinski LC, Papenhausen PR, Ballester OF. Surface phenotype in plasma cell dyscrasia and the relationship to karyotype and cytomorphology. American Society of Hematology, Denver, Colorado, 1991.
10. Ballester OF, Burgess J, Balducci L. Serum interleukin-6 (IL-6) and C reactive protein (CRP) in multiple myeloma. International Society of Hematology, London, UK, August, 1992
11. Ballester OF, Moscinski LC, Saba HI, Spiers ASD, Klein C. Interleukin-6 (IL-6): A growth factor or a differentiation factor for multiple myeloma. American Society of Hematology, Anaheim, California, December, 1992.
12. Agaliotis D, Janssen W, Fields K, Hiemenz J, Zorsky P, Ballester O, Perkins J, and Eifenbein G. Recovery of granulopoiesis after high dose chemotherapy and autologous stem cell transplantation is dependent upon source of stem cells, use of growth factors, and treatment regimen. 1993 Associates Meeting, FACP, Miami, April, 1993.
13. Fields KK, Eifenbein GJ, Perkins JB, Ballester OF, Hiemenz JW and Zorsky PE. Results of phase I-II escalation trials and autologous stem cell rescue (ASCR) for the treatment of metastatic and early stage high risk breast cancer. 18th ICC Conference, Stockholm, Sweden, 1993.

14. Ballester, OF, Moscinski LC, Chaney JV, Lyman GH. Growth fraction and interleukin-6 in multiple myeloma. IVth International Workshop on Multiple Myeloma. Mayo Clinic, Rochester, Minnesota, October 1993.
15. Zhang X, Ballester OF, Janssen WE. Conditions for colonogenic assay of myeloma stem cells within human bone marrow. IVth International Workshop on Multiple Myeloma. Mayo Clinic, Rochester, Minnesota, October 1993.
16. Moscinski LC, Ballester OF, Blair P, Saba HI, Spiers ASD. Plasma cell phenotype as a prognostic indicator in multiple myeloma. IVth International Workshop on Multiple Myeloma. Mayo Clinic, Rochester, Minnesota, October, 1993.
17. Moscinski LC, Ballester OF, Hill B, Fairbee SL, Coris E. Exogenous IL-6 fails to promote proliferation or phenotypic transformation in multiple myeloma. American Society of Hematology. St. Louis, Missouri, December, 1993.
18. Ballester OF, Moscinski LC, Fields KK, Hiemenz JW, Zorsky PE, Goldstein SC, Saba HI, Spiers ASD, Kronish LE, Effenbein GJ. Phase I-II Trial of DC-IE: a Novel, Intensive Induction Chemotherapy Regimen for Multiple Myeloma (MM). American Society of Hematology. Nashville, Tennessee, December 2-6, 1994.
19. Garland LL, Ballester OF, Vasey FB, Benson K, Moscinski LC, Farmelo MJ, Rodriguez MJ, Rappaport DP. Multiple Myeloma in Women with Silicone Breast Implants. Immunology of Silicone. National Cancer Institute, Bethesda, Maryland, March 13-14, 1995.
20. Ballester O, Fields KK, Hiemenz J, Zorsky P, Goldstein S, Janssen W, Beach B, Effenbein G. Intensive induction chemotherapy with DC-IE, followed by consolidation with BUCY and autologous peripheral blood stem cell transplantation for high risk multiple myeloma. 5th International Workshop on Multiple Myeloma. Le Baule, France. September 1995.
21. Garland L, Tricot G, Ballester O, Naucke S, Vaught L, Vesole D, Jagannath S, Barlogie B, Moscinski L. Multiple Myeloma in patients with silicone breast implants: a series from two referral centers. 5th International Workshop on Multiple Myeloma. Le Baule, France. September 1995.
22. Moscinski LC, Ballester OF, Hill B, Farmelo MJ. Exogenous IL-6 induces IL-6 secretion in bone marrow supernatants from patients with multiple myeloma. 5th International Workshop on Multiple Myeloma. Le Baule, France. September, 1995.
23. Ballester O, Trudeau W, Moscinski LC, Hill B. High rate of molecular residual disease in patients with multiple myeloma in clinical complete remission following high-dose therapy and autologous stem cell transplantation. 5th International Workshop on Multiple Myeloma. Le Baule, France. September, 1995.
24. Ballester OF, Moscinski LC, Farmelo MJ, Mullen MG, Hill B. Clinical significance of interleukin-6 and soluble interleukin-6 receptor expression in the bone marrow of patients with plasma cell disorders. American Society of Hematology, Seattle, Washington. December 1995.
25. Ballester O, Zorsky P, Janssen W, Fields KK, Hiemenz J, Goldstein S, Perkins J, Rosen R, Effenbein G. High dose therapy with autologous peripheral blood stem cell transplantation in patients with multiple myeloma and end-stage renal failure. American Society of Hematology. Seattle, Washington. December, 1995.
26. Ballester O, Sullivan P, Hendrix L, Perkins J, Hiemenz J, Fields K, Goldstein S, Sullivan D, Effenbein G. Interleukin-3 is effective for engraftment failure following high-dose therapy and autologous stem cell transplantation. International; Society for Experimental Hematology. New York, New York, August, 1996.
27. Tummala R, Ballester O, Janssen W, Fields K, Hiemenz J, Goldstein S, Perkins J, Rosen R, Saez R, Effenbein G. High dose therapy with autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal failure. International Society for Experimental Hematology.

New York, New York, August, 1996.

28. Thorton CO, Ballester OF, Greenfield GB. Progression of bone disease in multiple myeloma patients treated with high-dose therapy and autologous stem cell transplantation. American Society of Hematology. Orlando, Florida, December, 1996.
29. Vescio RA, Schiller GJ, Stewart AK, Anderson KC, DiPersio JF, Noga S, Ballester OF, Rugo H, Freytes CO, Wu CH, Han EJ, Cao J, Belson DJ, Berenson JB. Quantitative assessment of myeloma peripheral blood and bone marrow tumor burden in patients undergoing autologous transplantation. American Society of Hematology. Orlando, Florida, December, 1996.
30. Dalton W, Greipp P, Greenberg P, Stiff P, Ballester O, Friedenber W, Salmon S, Kyle R, Charnick S, Pearce T. Phase I study of the chemosensitizer SDZ PSC 833 in combination with VAD chemotherapy to reverse multidrug resistance. American Society of Hematology. Orlando, Florida. December, 1996.
31. Vescio, A. Stewart, O. Ballester, S. Noga, H. Rugo, C. Freytes, E. Stadtmauer, N. Kogut, S. Tarantolo, P. Stiff, G. Schiller, A. Sing, M. White, C. Jacobs, J. DiPersio, K. Anderson, J. Berenson. Circulating Multiple Myeloma Cell Burden Predicts Disease Relapse Following Autologous Transplantation. Proc of Amer Soc Hematology, Abstract #397, poster 397-I, 1998
32. Krieger, G. Schiller, J.R. Berenson, K. Stewart, S.J. Noga, O. Ballester, S. Tarantolo, P. Stiff, D. Kuhn, E. Scherzo, A. Sing, C. Jacobs, J.M. White, J. DiPersio. Collection of peripheral blood progenitor cells (PBPC) Based on a Rising WBC and Platelet Count Significantly Increases the Number of CD34+ Cells. Proc of Amer Soc Hematology, Abstract #494, poster 494-I, 1998
33. C. Freytes, A.K. Stewart, R. Vescio, G. Schiller, O. Ballester, S. Noga, H. Rugo, E. Stadmauer, F. Sahebi, S. Tarantolo, P. Stiff, J. Meharchard, R. Schlossman, R. Brown, H. Tully, C. Jacobs, J. DiPersio, K. Anderson, J. Berenson, A. Sing. CD34 Selection did not Delay Immune Recovery nor Increase Frequency of Infections in Multiple Myeloma Patients Transplanted on a Phase III Trial. Proc of Amer Soc Hematology, Abstract #2724, poster 581-IV, 1998
34. Stewart, R. Vescio, G. Schiller, O. Ballester, S. Noga, H. Rugo, C. Freytes, E. Stadmauer, F. Sahebi, S. Tarantolo, P. Stiff, J. Meharchard, R. Schlossman, R. Brown, H. Tully, A. Sing, C. Jacobs, J. DiPersio, K. Anderson, J. Berenson,. Phase III Study Evaluating CD34 Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in 190 Patients with Advanced Multiple Myeloma. Proc of Amer Soc Hematology, Abstract #2733, poster 590-IV, 1998
35. Ballester, O., T. Fang, G. Bruno, P. Wilcox, P. Vashi, M. Payne, M. Eldibany, B. Tan. Adpotive Immunotherapy with Donor Lymphocyte Infusion (DLI) and IL-2 After High-Dose Therapy (HDT) And Autologous Stem Cell (ASC) Rescue For Relapsed/Refractory Multiple Myeloma. American Society of Hematology, San Francisco, December, 2000.
36. Bruno, G., O. Ballester, P. Wilcox, T. Fang, M. Payne, B. Tan. Midet+Rituximab Is An Effective Regimen For Poor Prognosis Non-Hodgkin's Lymphoma Patients Receiving High Dose Therapy. American Society of Hematology, San Francisco, December, 2000.
37. Sivasubramanian V, Dodds S, Lyman G, Hiemenz J, Maloy B, Morgalis M, Cirenza E, Ballester O. Low dose dopamine/heparin for the pre-emptive treatment of veno-occlusive disease of the liver in patients receiving busulfan/cyclophosphamide and allogeneic or autologous stem cell transplantation. Tandem BMT Meetings. IBMTR-ABMT-ASBMT. Orlando, Florida. March 2002.
38. Kuthiala SK, Lyman GH, Ballester O. Hematopoietic Stem Cell Transplantation Phase III Clinical Trials for patients with Hematological Malignancies in the USA: lessons to be learned from the European experience, Oral presentation. American Society of Hematology. San Diego, California. December, .2004

#### **ABSTRACTOS PUBLICADOS:**

1. Ballester OF, Reddy IS and Mirchandani I: Bone marrow culture characteristics in aleukemic

- leukemia and correlation with clinical course. *Blood* 54 (Supp. 1):168a, 1979.
2. Ballester OF, Burek C, Shurafa M and Toben H: Antibody responses to pneumococcal polysaccharide type III in patients with Multiple Myeloma. Fourth International Congress of Immunology. Paris, France. 1980.
  3. Ballester OF, Toben H, Shurafa M, Kumar K, and Davayar R: Non-Hodgkin's lymphoma in remission: correlation of in-vitro mitogenic responses with in-vivo antibody production. 18th Congress of the International Society of Hematology. Montreal, Canada, 1980.
  4. Ballester OF and Prasad A: Anergy, zinc deficiency and decreased nucleoside phosphorylase (NP) activity in patients with sickle cell anemia (SCA). *Clin Research* 29 (4):765A, 1981.
  5. Briggs W, Migdal S, Ballester OF, Abu-Hamdan D, Mahajan S, Prasad A and McDonald F: Antibody (ab) response to pneumococcal vaccine (Pv) in Zinc (Zn) treated and untreated hemodialysis patients (Hd). *Clin Research* 30 (2):486a, 1982.
  6. Palutke M, Ratanatharathron V, Ballester OF, Shurafa L and Tabaczka P: T cell chronic lymphocytic leukemia composes of two populations of cells, one with a helper the other suppressor phenotype. *Blood* 62 (Supp. 1):52a, 1983.
  7. Ballester OF, Abdallah J and Prasad A: Impaired IgM antibody responses to an influenza virus vaccine in sickle cell anemia (SCA) patients. *Blood* 62 (Supp. 1): 52a, 1983.
  8. Ballester OF, Saba HI, Papenhausen P, Moscinski L, and Weintraub R: Extramedullary (EM) blast crisis (BC) in chronic myelogenous leukemia (CML): abnormalities of chromosome 19 with evidence of clonal evolution. *Blood* 74 (Supp. 1):352a, 1989.
  9. Ballester OF, Spiers ASD, and Grattan J: Autoimmune hemolytic anemia (AIHA) accompanying treatment with alpha interferon (IFN) in a patient with chronic granulocytic leukemia (CGL). *Blood* 74 (Supp. 1):352a, 1989.
  10. Saba HI, Ballester OF, Whiden R, Browarsky I, Toney J: Acute lymphoblastic leukemia (ALL) in a hemophiliac with HIV infection. *Blood* 74 (Supp. 1):407a, 1989.
  11. Spiers ASD, Ballester OF, McPherson GG: A low-dose chemotherapy regimen (Bleo-NOVA) is effective for control of Kaposi's sarcoma in patients with AIDS. *Blood* 74 (Supp. 1):408a, 1989.
  12. Papenhausen P, Saba HI, Ballester OF, Moscinski LC. Three different 14q+ chromosomes in rapid transforming chronic lymphocytic leukemia (CLL). *Blood* 76 (Supp. 1):958a, 1990.
  13. Spiers ASD, Saba HI, Ballester OF, Moscinski LC, Sanderson RA. Interferon (IFN) therapy for chronic granulocytic leukemia (CGL): Thrombocytopenia, morphologic and cytogenetic changes in bone marrow and prolonged disease control after discontinuing treatment. *Blood* 76 (Supp. 1): 1282a, 1990.
  14. Spiers ASD, Saba HI, Ballester OF, Morgan MB, Moscinski LC. Purple people with lymphoid neoplasms: A new clinicopathologic syndrome. *Blood* 76 (Supp. 1):1486a, 1990.
  15. Ballester OF, Morelli G, Saba HI, Foulis P. An IgG time-dependent, acquired factor V (FV) inhibitor. *Blood* 76 (Supp. 1):163a, 1990.
  16. Ballester OF, Edwards TB, Saba HI, Nelson R, Foulis P. Polycythemia in an HIV-1 infected patient: Response to zidovudine (AZT) therapy. *Blood* 76 (Supp. 1):1924a, 1990.
  17. Saba HI, Ballester OF, Bowarsky I, Moscinski LC. Localized rectal Hodgkin's disease in a patient with AIDS: Management with surgical resection. *Blood* 76 (Supp. 1):1963a, 1990.
  18. Ballester OF, Saba HI, Morelli GA, Balducci L, Fabri PJ. Heparin-Induced Thrombocytopenia (HIT) and Thrombosis in an Elderly Patient. *J Am Ger Soc.* 39, A77, 1991.

19. Ballester OF, Papenhausen P, Moscinski LC, Foulis P, Saba HI. Cytogenetic Analysis of Interleukin-6 (IL-6) Stimulated Myeloma Cells. *Blood* 78 (Suppl 1):463a, 1991.
20. Ballester O, Moscinski LC, Balducci L, Burgess J, Saba HI. Interleukin-6 (IL-6) and Beta 2 Microglobulin (B2M) Expression in Myeloma Cell Cultures. *Blood* 78 (Suppl 1):463a, 1991.
21. Papenhausen PR, Moscinski LC, Ballester O. Novel Merged Clonal Abnormalities and Unusual Derivatives in Successive CML-BC. *Blood* 78 (Suppl 1):458a, 1991.
22. Moscinski LC, Papenhausen PR, Ballester O. Surface Phenotyping in Plasma Cell Dyscrasia and the Relationship to Karyotype and Cytomorphology. *Blood* 78 (Suppl 1):116a, 1991.
23. Ballester O, Corrado C, Moscinski L, Bruno S, Burgess J. Clinical significance of serum interleukin-6 (IL-6) levels in patients with multiple myeloma (MM). *Proceedings ASCO* 11:98, 1992.
24. Ballester O, Burgess J, Balducci L. Serum interleukin-6 and C reactive protein (CRP) in multiple myeloma (MM). *Abstracts of the 24th Congress of the International Society of Hematology*, p. 124, 1992.
25. Ballester OF, Moscinski LC, Saba HI, Spiers ASD, Klein C. Interleukin-6 (IL-6): A growth factor or a differentiation factor for multiple myeloma. *Blood* 80 (Suppl 1):123a, 1992.
26. Berman B, Liv E, Lyman G, Sanderson R, Ballester O. Granulocyte colony stimulating factor (G-CSF) in a high risk population of patients with acute nonlymphocytic leukemia (ANLL) receiving induction chemotherapy. *Blood* 80 (Suppl 1):446a, 1992.
27. Saba HI, Ismail R, Shamim F, Spiers ASD, Lyman GH, Ballester OF, Balducci L, Moscinski L, Greene J, Klein C, Sanderson R. Acute myeloid leukemia in the elderly: An analysis of 67 patients. *Blood* 80 (Suppl 1):458a, 1992.
28. Saba HI, Ismail R, Shamim F, Spiers ASD, Lyman GH, Ballester OF, Balducci L, Moscinski L, Greene J, Klein C, Sanderson R. Acute leukemic transformation in myelodysplastic syndrome. *Blood* 80 (Suppl 1):459a, 1992.
29. Agalotis D, Janssen W, Fields K, Hiemenz J, Zorsky P, Ballester O, Perkins J, and Eifenbein G. Recovery of granulopoiesis after high dose chemotherapy and autologous stem cell transplantation is dependent upon source of stem cells, use of growth factors, and treatment regimen. *Journal of Clinical Oncology*. *Proceedings ASCO*, Abstract No 1585, 1993.
30. Hiemenz JW, Janssen WE, Fields KK, Zorsky PE, Ballester OF, Perkins JB, Eifenbein GJ. Factors affecting the rate of engraftment following autologous stem cell reinfusion: Methods of peripheral blood stem cell mobilization. *Exp Hematol* 21:1164, 1993.
31. Eifenbein GJ, Janssen WE, Hiemenz JW, Fields KK, Zorsky PE, Ballester OF, Perkins JB. Factors affecting the rate of engraftment following autologous stem cell rescue: Conditioning regimen. *Exp Hematol* 21:1164, 1993.
32. Agalotis DP, Fields KK, Ballester OF, Hiemenz JW, Zorsky PE, Janssen WE, Perkins JB, Pach LD, Eifenbein GJ. Event free survival in patients with metastatic breast cancer undergoing high dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. *Exp Hematol* 21:1130, 1993.
33. Moscinski LC, Ballester OF, Janssen WE. Granulocyte-colony stimulating factor for patients with hypoplastic acute myelogenous leukemia not receiving induction chemotherapy. *Exp Hematol* 21:1102, 1993.
34. Ballester OF, Janssen WE, Perkins JB, Farmelo MJ, Smilee R. Serum interleukin-6 levels and marrow engraftment after high dose chemotherapy and autologous stem cell transplantation. *Exp Hematol* 21:1174, 1993.



35. Ballester OF, Moscinski LC, Chaney JV, Lyman GH. Growth fraction and interleukin-6 in multiple myeloma. Proceedings of the IV International Workshop on Multiple Myeloma. Mayo Clinic, Rochester Minnesota, October 1993.
36. Zhang X, Ballester OF, Janssen WE. Conditions for colonogenic assay of myeloma stem cells within human bone marrow. Proceedings of the IV International Workshop on Multiple Myeloma. Mayo Clinic, Rochester Minnesota, October 1993.
37. Moscinski LC, Ballester OF, Blair P, Saba HI, Spiers ASD. Plasma cell phenotype as a prognostic indicator in multiple myeloma. Proceedings of the IV International Workshop on Multiple Myeloma. Mayo Clinic, Rochester Minnesota, October 1993.
38. Moscinski LC, Ballester OF, Hill B, Fairbee SL, Coris E. Exogenous IL-6 fails to promote proliferation or phenotypic transformation in multiple myeloma. Blood 82 (supp 1) 260a, 1993.
39. Ballester OF, Janssen W, Moscinski LC, Saba M, Farmelo M, Hill, B. Interleukin-6 levels in the Bone marrow of multiple myeloma patients after intensive chemotherapy. Blood 82 (Suppl. 1):559a, 1993.
40. Zhang, XJ, Janssen WE, Ballester OF, Moscinski L. 2-Chlorodeoxyadenosine induces apoptosis of myeloma cells. Blood 82 (Suppl. 1): 581a, 1993.
41. Agaliotis D, Hiemenz J, Janssen WE, Fields K, Zorsky P, Ballester OF, Effenbein G. Successful HLA-Matched related allogeneic bone marrow (BM) engraftment with cadaveric donor cells. Blood 82 (Suppl. 1): 626a, 1993.
42. Ballester OF, Janssen WE, Effenbein G, Fields K, Hiemenz J, Zorsky P, Kronish L, Beach B, Foody M, Sherman M. Rapid engraftment following busulfan, cyclophosphamide and autologous peripheral blood stem cell (PBSC) transplantation for high risk hematological malignancies. Blood 82 (Suppl. 1): 626a, 1993.
43. Agaliotis D, Fields K, Ballester O, Hiemenz J, Zorsky P, Goldstein S, Janssen W, Effenbein G. Delayed renal toxicity following high dose ifosfamide (Ifos) in patients undergoing autologous bone marrow transplantation (BMT). FACP, 1993.
44. Effenbein G, Janssen W, Perkins J, Hiemenz J, Ballester O, Fields K, Goldstein S and Zorsky P. Pace of engraftment following high dose chemotherapy and autologous stem cell rescue depends on stem cell priming regimen. Proceedings of ASCO 13:115, 1994.
45. Zorsky P, Fields K, Effenbein G, Perkins J, Ballester O, Goldstein S, Janssen W, Hiemenz J, Kronish L, Beach B. A phase I-II study of high-dose ifosfamide, carboplatin, and etoposide (ICE) and autologous stem cell rescue (ASCR) for refractory lymphoma: Further evidence for dose intensity. Proceedings of ASCO 13:384, 1994.
46. Ballester OF, Agaliotis D, Moscinski LC, Fields KK, Hiemenz J, Zorsky P, Goldstein S, Saba HI, Spiers ASD, Effenbein G. DC-IE: A novel time-sequenced and dose intensive induction chemotherapy regimen for multiple myeloma (MM). Brit J Hematol, 87 (supp 1): 209, 1994.
47. Agaliotis D, Ballester O, Effenbein G, Janssen W, Fields K, Goldstein S, Hiemenz J, Zorsky P, Perkins J, Kronish L, Beach B. Autologous peripheral blood stem cell (PBSC) transplantation (T) following high dose busulfan/cyclophosphamide for the treatment of hematological malignancies is associated with rapid engraftment. Brit J Hematol, 87 (supp):24, 1994.
48. Hiemenz JW, Janssen WE, Ballester OF, Fields KK, Goldstein S, Zorsky PE, Effenbein GJ. Factors affecting the duration of neutropenia following high dose chemotherapy (HDC) and autologous stem cell reinfusion (ASCR). Abstract #077; 8th International Symposium of IHS, 1994.
49. Ballester OF, Agaliotis DP, Janssen WE, Fields KK, Hiemenz JW, Zorsky PE, Goldstein SC, and Effenbein GJ. Patterns of platelet recovery after busulfan/cyclophosphamide and peripheral blood stem cell transplantation in patients with hematological malignancies. Exp Hematol 22:782, 1994.

50. Perkins JB, Cremers KA, Fields KK, Janssen WE, Ballester OF, Goldstein SC, Hiemenz JW, Zorsky PE and Elfenbein GJ. Differences in engraftment rate between two groups of breast cancer patients treated with the same high dose chemotherapy regimen: Potential contributing factors for hematopoietic recovery. *Exp Hematol* 22:782, 1994.
51. Elfenbein GJ, Fields KK, Perkins JB, Ballester OF, Goldstein SC, Hiemenz JW and Zorsky PE. Time to relapse after high dose chemotherapy with two novel regimens for metastatic breast cancer. *Exp Hematol* 22:780, 1994.
52. Janssen We, Hiemenz JW, Fields KK, Zorsky PE, Ballester OF, Goldstein SC, Smilee R, Kronish L, and Elfenbein GJ. Peripheral blood "stem cells" do not always produce faster engraftment than bone marrow in autotransplantation. *Exp Hematol* 22:765, 1994.
53. Elfenbein GJ, Janssen WE, Hiemenz JW, Fields KK, Zorsky PE, Ballester OF, Goldstein SC, Smilee R, Kronish L. Growth factor "stimulated" bone marrow stem cells provide as rapid engraftment as do growth factor "mobilized" peripheral blood stem cells. 7th International Symposium Auto BMT., Arlington, TX, 1994. (In Press)
54. Agaliotis D, Ballester O, Fields, Hiemenz J, Zorsky P, Goldstein S, Janssen W, Ramirez G, and Elfenbein G. Renal Toxicity patterns following high dose ifosfamide (IFOS) and autologous stem cell transplantation (ASCT). *Proceedings of ASCO* 13:156, 1994.
55. Elfenbein G, Janssen W, Perkins J, Hiemenz J, Ballester O, Fields K, Goldstein S, and Zorsky P. Pace of engraftment following high dose chemotherapy and autologous stem cell rescue depends on stem cell priming regimen. *Proceedings of ASCO* 13:115, 1994.
56. Zorsky P, Fields K, Elfenbein G, Perkins J, Ballester O, Goldstein S, Janssen W, Hiemenz J, Kronish L, Beach B. A phase I-II study of high-dose ifosfamide, carboplatin and etoposide (ICE) and autologous stem cell rescue (ASCR) for refractory lymphoma: Further evidence for dose intensity. *Proceedings of ASCO* 13:384, 1994.
57. Ballester OF, Agaliotis DP, Janssen WE, Fields KK, Hiemenz JW, Zorsky PE, Goldstein SC, and Elfenbein GJ. Patterns of platelet recovery after busulfan/cyclophosphamide and peripheral blood stem cell transplantation in patient with hematological malignancies. *Exp. Hematol.* 22:782, 1994.
58. Perkins JB, Cremers KA, Fields KK, Janssen WE, Ballester Of, Goldstein SC, Hiemenz JW, Zorsky PE and Elfenbein GJ. Differences in engraftment rate between two groups of breast cancer patients treated with the same high dose chemotherapy regimen: Potential contributing factors for hematopoietic recovery. *Exp Hematol* 22:782, 1994.
59. Elfenbein GJ, Fields KK, Perkins JB, Ballester OF, Goldstein SC, Hiemenz JW and Zorsky PE. Time to relapse after high dose chemotherapy with two novel regimens for metastatic breast cancer. *Exp Hematol* 22:780, 1994.
60. Janssen WE, Hiemenz JW, Fields KK, Zorsky PE, Ballester OF, Goldstein SC, Smilee R, Kronish L, and Elfenbein GJ. Peripheral blood "stem cells" do not always produce faster engraftment than bone marrow in autotransplantation. *Exp Hematol* 22:765, 1994.
61. Fields KK, Perkins JB, Ballester OF, Goldstein SC, Hiemenz JW, Zorksy PE, Pach LD, and Elfenbein GJ. Time to relapse following high dose chemotherapy for the treatment of poor prognosis breast cancer: Durable remissions beyond 24 months. *Breast Cancer Research & Treatment* 32 (suppl):63, 1994.
62. Spiers A, Ballester O, Saba H, Moscinski L, Sanderson R, Balducci L, Lyman G. The cadet regimen (carboplatin/ARA-C/daunorubicin/etoposide/thioguanine): An active combination in poor prognosis acute myeloid leukemia (AML). *Proceedings of ASCO* 13:307, 1005a, 1994.
63. Elfenbein GJ, Perkins JB, Fields KK, Ballester OF, Goldstein SC, Hiemenz JW, Janssen WE, Zorsky PE. Hematologic recovery after high dose Taxol, Novantrone, Thiotepa (TNT) and autologous stem

- cell transplant: Evaluation of the effects of stem cell source and taxol. *Blood* 84 (suppl. 1):707a, 1994.
64. Perkins JB, Fields KK, Elfenbein GJ, Ballester OF, Goldstein SC, Hiemenz JW, Zorsky PE. Use of GM-CSF (leukine<sub>R</sub>-sargramostim) as a chemoprotectant prior to ifosfamide, carboplatin, and etoposide: preliminary results of a randomized, controlled trial. *Blood* 84 (suppl. 1): 585a, 1994.
  65. Goldstein SC, Alkan S, Janssen W, Thompson J, Moscinski L, Ballester OF, Hiemenz J, Zorsky P, Perkins JB, Fields K, Elfenbein GJ. Chemomobilization of BCR/ABL-negative peripheral blood stem cells for autologous transplantation in chronic myelogenous leukemia. *Blood* 84 (suppl. 1): 710a, 1994.
  66. Ballester OF, Moscinski LC, Fields K, Hiemenz J, Zorsky P, Goldstein SC, Saba HI, Spiers ASD, LE, Elfenbein GJ. Phase I-II Trial of DC-IE: A novel, intensive induction chemotherapy regimen for multiple myeloma (MM). *Blood* 84 (suppl. 1):702a, 1994.
  67. Garland LL, Ballester OF, Vasey FB, Ezrailson EG, Moscinski LC, Craddock L, Benson K, Rappaport DP. Multiple myeloma (MM) & monoclonal gammopathies (MG) in women with silicone breast implants. *Blood* 84 (suppl. 1): 653a, 1994.
  68. Spiers A, Saba H, Vieson K, Ballester O, Moscinski L, Dinwoodie W. Mycosis fungoides and Sezary syndrome: Treatment with carboplatin and etoposide by continuous intravenous infusion (CIVI). *Blood* 84 (suppl. 1) 169a, 662, 1994.
  69. Janssen WE, Perkins JB, Hiemenz JW, Fields KK, Zorsky PE, Ballester OF, Goldstein SC, Smilee R, Kronish L, Elfenbein GJ. Granulocyte recovery is not different following auto-transplant with G-CSF primed bone marrow or G-CSF mobilized peripheral blood "stem cells". *Blood* 84 (suppl. 1):95a, 1994.
  70. Fields K, Perkins J, Elfenbein G, Ballester O, Hiemenz JW, Goldstein SC, Zorsky PE, and Kronish L. A phase I dose escalation trial of high dose TAXOL, NOVATRONE and THIOTEPA (TNT) followed by autologous stem cell rescue (ASCR): Toxicity. *Proceedings of ASCO* 14: 332 , 1995.
  71. Fang T, Zorsky P, Rodriguez-Paz G, Ballester O, Fields K, Goldstein S, Hiemenz J, Elfenbein G. Severe dilated cardiomyopathy after high dose cyclophosphamide and busulfan after allogeneic bone marrow transplant. Florida Division ACS meeting. Orlando, FL 1995.
  72. Janssen WE, Smilee RC, Perkins J, Fields KK, Zorsky PE, Ballester OF, Goldstein SC, Kronish L, Beach B, Elfenbein GJ. Platelet and neutrophil recovery following auto-transplant with G-CSF primed marrow or G-CSF mobilized blood is not different. *Exp Hematol* 23: 863, 1995.
  73. Perkins JB, Elfenbein GJ, Janssen WE, Fields KK, Ballester OF, Hiemenz JW, Zorsky PE, Goldstein SC. Lack of difference in rate of hematopoietic recovery after bone marrow and peripheral blood stem cell infusion versus peripheral blood stem cells alone. *Exp Hematol* 23: 761, 1995.
  74. Ballester O, Zorsky P, Janssen W, Fields K, Hiemenz J, Goldstein S, Perkins J, Rosen R, Elfenbein G. High dose therapy with autologous peripheral blood stem cell transplantation in patients with multiple myeloma and end-stage renal failure. *Blood* 86 (suppl 1):206a, 1995.
  75. Zorsky P, Ballester O, Goldstein S, Hiemenz J, Janssen W, Fields K, Elfenbein G. Comparison of cyclosporine (CSA)+Methylprednisolone (MedPred) vs CSA+Methotrexate(MTX) prophylaxis in HLA identical allogeneic bone marrow transplantation. *Blood* 86 (suppl 1):396a, 1995.
  76. Zorsky P, Fang T, Janssen W, Ballester O, Fields K, Goldstein S, Hiemenz J, Elfenbein G. The WBC recovery rate after priming with CYVP16+G-CSF is a determinant of ANC recovery and survival after BUCY2 + autologous peripheral blood stem cell rescue (ASCR). *Blood* 86 (suppl 1):944a, 1995.
  77. Hiemenz JW, Janssen WE, Smilee RC, Perkins JB, Fields KK, Ballester OF, Goldstein SC, Kronish LE, Zorsky PE, Elfenbein GH. Neutrophil and platelet recovery following auto-transplant with G-CSF primed marrow or G-CSF mobilized blood is not different. 2d International Symposium on febrile

neutropenia. Brussels, Austria 1995.

78. Eifenbein GJ, Perkins JB, Janssen WE, Fields KK, Ballester OF, Goldstein SC, Hiemenz JW, Sackstein R, Partyka JS. Recovery of granulopoiesis after autologous peripheral blood stem cell transplantation (PBSCT) varies with the high dose regimen (HDREG). Keystone Symposium. Keystone, CO 1996.
79. Partyka JS, Perkins JB, Janssen WE, Ballester OF, Fields KK, Goldstein SC, Hiemenz JW, Sackstein R, Eifenbein GJ. Granulocyte and platelet recovery after autologous peripheral blood stem cell transplant (PBSCT) depends on mobilizing regimen (MOREG). Keystone Symposium. Keystone, CO 1996.
80. Fields KK, Ballester OF, Goldstein SC, Hiemenz JW, Perkins JB, Machesney LD, Eifenbein GJ. Age effects in patients undergoing autologous bone marrow or peripheral blood stem cell transplantation. ASCO, 1996.
81. Ballester, OF, Moscinski, LC, Farmelo, MJ, Muller, MG, Hill, B. Clinical significance of IL-6 and soluble IL-6 receptor expression in the bone marrow of patient with plasma cell disorders. Blood 86 (suppl. 1): 63a, 1995.
82. Moscinski LC, Ballester OF, Saba HI and Blair P. Mature plasma cells from all patients with multiple myeloma possess adhesion proteins, but with variable patterns of expression. Blood 88 (suppl 1):393a, 1996.
83. Goldstein S, Kronish L, Ballester O, Hiemenz J, Sullivan D, Partyka J, Perkins J, Janssen W, Eifenbein G, Fields KK. Phase I/II trial of high dose ifosfamide, carboplatin and etoposide (ICE) at maximum tolerated dosage (MTD) with autologous stem cell rescue for refractory lymphoma. Blood 88 (suppl 1):124a, 1996.
84. Thorton CO, Ballester OF, Greenfield GB. Progression of bone disease in multiple myeloma patients treated with high-dose therapy and autologous stem cell transplantation. Blood 88 (suppl 1):481a, 1996.
85. Vescio RA, Schiller GJ, Stewart AK, Anderson KC, DiPersio JF, Noga S, Ballester OF, Rugo H, Freytes CO, Wu CH, Han EJ, Cao J, Belson DJ, Berenson JB. Quantitative assessment of myeloma peripheral blood and bone marrow tumor burden in patients undergoing autologous transplantation. Blood 88 (suppl 1):641a, 1996.
86. Dalton W, Greipp P, Greenberg P, Stiff P, Ballester O, FriedenberG W, Salmon S, Kyle R, Charnick S, Pearce T. Phase I study of the chemosensitizer SDZ PSC 833 in combination with VAD chemotherapy to reverse multidrug resistance. Blood 88 (suppl 1): 663a, 1996.
87. Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, Freytes C, Stadtmayer E, Kogut N, Tarantolo S, Stiff P, Pineiro L, Dalton W, Ho A, Vescio R, Benyunes M, Jacobs C, DiPersio J, Anderson K, Berenson J. A Phase III Study Evaluating CD34+ Selected versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation for Patients with Advanced Multiple Myeloma: Engraftment Results. Proc of Amer Soc Hematology, Abstract #960, 1997
88. Moscinski LC, Ballester OF, Saba JI, Blair P. IL-6 Receptor and Adhesion Protein Profiles as Prognostic Features in Multiple Myeloma. Proc of Amer Soc Hematology, Abstract #2343, 1997
89. Vescio R, Stewart A, Ballester O, Noga S, Rugo H, Stadtmayer E, Kogut N, Tarantolo S, Stiff P, Pinero L, Dalton W, Ho A, Schiller G, Benyunes M, Jacobs C, DiPersio J, Anderson K, Berenson J. Increase in Circulating Tumor Cell Burden During Mobilization Chemotherapy Predicts for Relapse After Autologous Transplantation in Multiple Myeloma Patients. Proc of Amer Soc Hematology, Abstract #2515, 1997
90. Vescio R, Stewart A, Ballester O, Noga S, Rugo H, Freytes C, Stadtmayer E, Kogut N, Tarantolo S, Stiff P, Pinero L, Dalton W, Ho A, Schiller G, Benyunes M, Jacobs C, DiPersio J, Anderson K, Berenson J. Myeloma Cell Tumor Reduction in PBPC autografts Following CD34 Selection: The

Results of a Phase III Trial Using the CEPRATE<sup>®</sup> Device. Proc of Amer Soc Hematology, Abstract #1872, 1997

91. Vescio R, Wu C, Rettig M, Stewart A, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Kogut N, Tarantolo S, Stiff P, Pinero L, Dalton W, Ho A, Schiller G, Benyunes M, Jacobs C, DiPersio J, Anderson K, Berenson J. The Detection of KSHV is Increased by Mobilization Chemotherapy and Reduced in Autografts by CD34-selection. Proc of Amer Soc Hematology, Abstract #2516, 1997
92. Ballester O, Saez RA, Goldstein SC, Kronish L, Perkins J, Eifenbein G, Hiemenz J, Sullivan D, Fields K. Autologous Stem Cell Transplantation (ASCT) for Acute Leukemia: Prolonged Event-free Survival for Patients in First Complete Remission (CR1). Proceedings of ASCO, Abstract #89, 1997
93. Saez RA, Goldstein S, Kronish L, Perkins J, Partyka J, Zorsky P, Eifenbein G, Hiemenz J, Ballester O, Sullivan D, Fields K. Venous-occlusive Disease of the Liver (VOD) and Disease Status Pre-transplant predict outcome in allogeneic patients (Allo-BMT) Treated with cyclosporine/ methotrexate (CSA/MTX) as Graft-versus-Host Disease (GVHD) Prophylaxis. Proceedings of ASCO, Abstract #441, 1997
94. Fields KK, Partyka JS, Perkins, Saez RA, Goldstein SC, Sullivan DM, Hiemenz JW, Ballester OF, Kronish LC, Eifenbein GJ. Cyclophosphamide and Taxol<sup>®</sup> is an Active Salvage Regimen in Patients with Anthracycline Refractory Metastatic Breast Disease. Proceedings of ASCO, Abstract #588, 1997
95. Perkins JB, Fields KK, Hiemenz JW, Goldstein SC, Ballester OF, Kronish LC, Eifenbein GJ. Clinical Outcomes Following Several Novel High-Dose Regimens with Autologous Stem Cell Rescue for the Treatment of Epithelial Carcinoma of the ovary. Proceedings of ASCO, Abstract #1341, 1997
96. Ballester O, Moscinski L, Lyman G, Perkins J, Eifenbein G, Goldstein S, Sullivan D, Saez R, Fields K. Plasmablastic Morphology and Proliferative Compartment as Prognostic Indicators for Multiple Myeloma Patients Treated with High-Dose Therapy and Autologous Stem Cell Transplants. Proceedings of ASCO, Abstract #73, 1998
97. Eifenbein GJ, Ballester OF, Janssen WE, Fields KK, Partyka JS. High Dose Therapy with Busulfan and Cyclophosphamide Followed by Autologous Peripheral Blood Stem Cell Transplant for Myelomas and Lymphomas. Proceedings of ASCO, Abstract #348, 1998.
98. Ballester OF, Wilcox P, Musick R, Tan B. Rituximab Can Be Safely Included As Part Of High-Dose Therapy / Autologous Stem Cell Transplantation For Patients With Non-Hodgkin's Lymphoma. Blood; Proc of Amer Soc Hematology, Abstract #4552, 1998
99. Ballester OF, Wilcox P, Hill C, Payne M, Tan B, Williams S, Sanchez R. Peripheral Blood CD34+ Count Predicts The Adequacy Of Stem Cell Collection For Autologous Transplants Blood; Proc of Amer Soc Hematology, Abstract #4279, 1998
100. Freytes CO, Stewart AK, Vescio R, Schiller, G, Ballester O, Noga S, Rugo H, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Jacobs S, DiPersio J, Anderson K, Berenson J, Sing A. CD34 Selection Did Not Delay Immune Recovery Nor Increase Frequency of Infections in Multiple Myeloma Patients Transplanted on a Phase III Trial. Proc of Amer Soc Hematology, Abstract #2724, 1998
101. Vescio R, Stewart A, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Kogut N, Tarantolo S, Stiff P, Schiller G, Sing A, White M, Jacobs C, DiPersio J, Anderson K, Berenson J. Circulating Multiple Myeloma Cell Burden Predicts Disease Relapse Following Autologous Transplantation. Proc of Amer Soc Hematology, Abstract #397, 1998
102. Krieger MA, Schiller G, Berenson JR, Stewart K, Noga SJ, Ballester O, Tarantolo S, Stiff P, Kuhn D, Scherzo E, Sing A, Jacobs C, White JM, DiPersio J. Collection of Peripheral Blood Progenitor Cells (PBPC) Based on a Rising WBC and Platelet Count Significantly Increases the Number of CD34+ Cells. Proc of Amer Soc Hematology, Abstract #494, 1998

103. Elfenbein GJ, Ballester OF, Partyka JS, Fields KK, Janssen WE. Is Bone Destruction the Reason Why Myeloma Patients Engraft More Rapidly After Stem Cell Transplantation? Proc of Amer Soc Hematology, Abstract #4134, 1998
104. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmuer E, Sahebi F, Tarantolo S, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Sing A, Jacobs C, DiPersio J, Anderson K, Berenson J. Phase III Study Evaluating CD34 Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in 190 Patients with Advanced Multiple Myeloma. Proc of Amer Soc Hematology, Abstract #2733, 1998
105. Fang, P. Wilcox, S. Williams, R. Musick, O. Ballester. High Dose Ifosfamide, Carboplatin, with Escalating Doses of Docetaxel and Autologous Stem Cell Transplantation for Refractory Malignancies. Proc of ASCO, Abstract #219, 1999
106. O Ballester, C. Rummel, J. Granick, R. Sanchez, A. Mellijor, P. Wilcox, R. Levin, S. Williams, T. Fang. Age and Patterns of Adjuvant Therapy for Patients With Stage II and III Breast Cancer. Proc of ASCO, Abstract #2326a, 1999.
107. Sivasubramanian V, Dodds S, Lyman G, Hiemenz J, Maloy B, Morgalis M, Cirenza E, Ballester O. Low dose dopamine/heparin for the pre-emptive treatment of veno-occlusive disease of the liver in patients receiving busulfan/cyclophosphamide and allogeneic or autologous stem cell transplantation. Biology of Blood and Marrow Transplantation 2002, 8: abstract #171.

## **SOPORTE FINANCIERO PARA INVESTIGACION:**

### Principal Investigator:

NIH Biomedical Research Support Grant 1980 - 1981  
Immunodeficiency in patients with non-Hodgkin's lymphoma in remission

### Principal Investigator:

Michigan State Department of Health Grant 1983 - 1984 and 1984 - 1985  
The role of viral infections in the etiology of complications in sickle cell anemia patients

### Principal Investigator:

NIH Grant 1983 - 1986  
Cellular immunity and neutrophil function in adult sickle cell anemia subjects

### Principal Investigator:

University of South Florida  
Biomedical research Grant 1990 - 1991  
Chromosomal analysis of Interleukin-6 stimulated myeloma cells

### Principal Investigator:

Moffitt Cancer Center Research Grant, 1990 - 1991  
Interleukin-6 and growth factor in multiple myeloma

### Principal Investigator:

CIBA Geigy Pharmaceutical Grant, 1990 - 1993  
Aredia in multiple myeloma

### Principal Investigator:

ORTHO BIOTECH Pharmaceutical Grant, 1991 - 1992  
The effect of subcutaneous r-HuEPO in patients with chronic lymphocytic leukemia

### Principal Investigator:

CellPro, Inc., 1994-1997  
A multi-center, randomized, controlled phase III study evaluating CD34+ selected vs. unselected, autologous peripheral blood progenitor cell transplantation in patients with multiple myeloma

### Principal Investigator:

Sandoz Pharmaceuticals Corporation, 1994 - 1996  
Compassionate need use of SDZ ILE 964 (rhIL-3) in patients with bone marrow failure syndromes

### Principal Investigator:

Sandoz Pharmaceuticals Corporation, 1995 - 1997  
A phase I study of vincristine, doxorubicin, dexamethasone (VAD) and SDZ PSC 833 therapy in subjects with refractory or relapsed multiple myeloma or low grade non-Hodgkin's lymphoma

### Principal Investigator

Novartis Pharmaceutical, 1998-2000.  
A randomized, double-blind, multi-center, comparative trial of IV Zoledronate (4 mg or 8 mg) vs. Aredia (90 mg), as an adjunct to standard therapies, in the treatment of multiple myeloma and breast cancer patients with cancer-related bone lesions.

### Principal Investigator

Fujisawa Healthcare, 1999-2000.  
A phase III, randomized, double-blind comparative trial of FK463 versus fluconazole for prophylaxis of fungal infections in patients undergoing a hematopoietic stem cell transplant.

Principal Investigator  
Berlex, 2004-5  
VAD plus CAMPATH for CD52+ multiple myeloma.

Principal Investigator  
Celgene 2003-2004  
A multicenter, randomized, parallel-group, double-blind, placebo-controlled study of CC-5013 plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma.